Sensoril®

DRUG2 trials

Sponsors

Natreon, Inc., K.N. Roy Chengappa

Conditions

Generalized Anxiety DisorderSchizoaffective DisorderSchizophrenia

Phase 2

A Clinical Trial to Study the Effects of Sensoril® for Patients With Generalized Anxiety Disorder

CompletedNCT01311180

Natreon, Inc.Generalized Anxiety Disorder

Start: 2011-03-31End: 2012-11-30Updated: 2015-04-21

Unknown Phase

Withania Somnifera: an Immunomodulator and Anti-inflammatory Agent for Schizophrenia

CompletedNCT01793935

K.N. Roy ChengappaSchizoaffective Disorder, Schizophrenia

Start: 2013-04-30End: 2016-07-07Updated: 2018-01-03

Related Papers

Adjunctive Use of a Standardized Extract of <em>Withania somnifera</em> (Ashwagandha) to Treat Symptom Exacerbation in Schizophrenia

The Journal of Clinical Psychiatry2018-07-0969 citations